Short answer
Vanda Pharmaceuticals Inc. (VNDA) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $52M (up 3.4% year over year) with net income of −$49M.
Q1 2026 key financials · XBRL
- Revenue
- $52M
- +3.4% YoY
- Net income
- −$49M
- −64.7% YoY
- Operating margin
- -97.1%
- EPS (diluted)
- −$0.82
- −64.0% YoY
Source: XBRL data from the Vanda Pharmaceuticals Inc. (VNDA) Q1 2026 10-Q on SEC EDGAR. USD.
Vanda Pharmaceuticals Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $51.7M, up 3% YoY from $50.0M
- Fanapt revenue $29.6M, up 26% YoY; strongest product performance
- HETLIOZ revenue $15.9M, down 24% YoY; weakest performance amid generic competition
- Cost of goods sold $3.2M, down 10% YoY from $3.5M
- Near-term headwinds: continued HETLIOZ generic pressure and Medicare Part D benefit redesign
Risk Factors
- No material changes to risk factors since the December 31, 2025 Annual Report
- No newly added quarterly risk factor identified
- No material regulatory, legal, or compliance risk updates disclosed
- No new operational, competitive, or market risks disclosed
- No new liquidity, debt, currency, or concentration risks disclosed
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Vanda Pharmaceuticals Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.